VIウイルス学的抑制が長期に 安定して得られている患者での薬剤変更

文献

  1. Iwamoto A, Taira R, Yokomaku Y et al. The HIV care cascade: Japanese perspectives. PLoS One. 12:e0174360. 2017.
  2. Miyazaki N, Sugiura W, Gatanaga H et al. The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum. Jpn J Infect Dis. 70:158-60. 2017.
  3. Lazarus JV, Safreed-Harmon K, Barton SE et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med. 14:94. 2016.
  4. Trottier B, Lake JE, Logue K et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 22:295-305. 2017.
  5. Daar ES, DeJesus E, Ruane P et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV. 5:e347-56. 2018.
  6. Kityo C, Hagins D, Koenig E et al. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. J Acquir Immune Defic Syndr. 82:321-28. 2019.
  7. Molina JM, Ward D, Brar I et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 5:e357-65. 2018.
  8. Wohl D, Clarke A, Maggiolo F et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 11:561-73. 2018.
  9. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 375:396-407. 2010.
  10. Orkin C, DeJesus E, Ramgopal M et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 4:e195-204. 2017.
  11. DeJesus E, Ramgopal M, Crofoot G et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 4:e205-13. 2017.
  12. Orkin C, Molina JM, Negredo E et al. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 5:e23-34. 2018.
  13. Johnson M, Kumar P, Molina JM et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 81:463-72. 2019.
  14. Punekar Y, Parks D, van Wyk J et al. IS DTG+3TC EFFECTIVE AND SAFE IN CLINICAL PRACTICE? EVIDENCE FROM REAL WORLD DATA. 23rd International AIDS Conference; July 6-10, 2020; Virtual.
  15. Greenberg L, Ryom L, Neesgaard B et al. Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV. Clin Infect Dis. 2020. Online ahead of print.
  16. van Wyk J, Ajana F, Bisshop F et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. Clin Infect Dis. 71:1920-2020.
  17. Perez-Molina JA, Rubio R, Rivero A et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 15:775-84. 2015.
  18. Arribas JR, Girard PM, Landman R et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 15:785-92. 2015.
  19. Pulido F, Ribera E, Lagarde M et al. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis. 65:2112-18. 2017.
  20. Fabbiani M, Gagliardini R, Ciccarelli N et al. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 73:1955-64. 2018.
  21. Llibre JM, Hung CC, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 391:839-49. 2018.
  22. Katlama C, Soulié C, Caby F et al. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 71:2646-50. 2016.
  23. Wijting I, Rokx C, Boucher C et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised noninferiority trial. Lancet HIV. 4:e547-54. 2017.
  24. Oldenbuettel C, Wolf E, Ritter A et al. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 22:169-72. 2017.
  25. Blanco JL, Rojas J, Paredes R et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 73:1965-71. 2018.
  26. Wijting IEA, Lungu C, Rijnders BJA et al. HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy. J Infect Dis. 218:688-97. 2018.
  27. Hocqueloux L, Raffi F, Prazuck T et al. Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clin Infect Dis. 69:1498-505. 2019.
  28. Braun DL, Turk T, Tschumi F et al. Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. Clin Infect Dis. 69:1489-97. 2019.
  29. Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 40:280-87. 2005.
  30. Pulido F, Arribas JR, Delgado R et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 22:F1-9. 2008.
  31. Nunes EP, Santini de Oliveira M, Merçon M et al. Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 10:368-74.
  32. Katlama C, Valantin MA, Algarte-Genin M et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 24:2365-74. 2010.
  33. Clumeck N, Rieger A, Banhegyi D et al. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother. 66:1878-85. 2011.
  34. Arribas JR, Girard PM, Paton N et al. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med. 17:358-67. 2016.
  35. Gatanaga H, Hayashida T, Tanuma J et al. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis. 56:1812-19. 2013.
  36. Sax PE, Rockstroh JK, Luetkemeyer AF et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV. Clin Infect Dis. 2020. Online ahead of print.
  37. Acosta RK, Willkom M, Andreatta K et al. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir Immune Defic Syndr. 85:363-71. 2020.

PAGE TOP

アンケートにご協力ください。

このページは役に立ちましたか?

コメント